Home>Media>Newsroom Media Newsroom - 2024 Glenmark Therapeutics Inc., USA launches Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1% (OTC) 19 AUG 2024 | READ MORE Glenmark Pharma reports consolidated revenue growth of 6.9%, EBITDA margin of 18.1%, and PAT margin of 10.5% YoY for Q1 FY 2024-25 14 AUG 2024 | READ MORE Glenmark Pharmaceuticals receives ANDA approval for Topiramate Capsules USP, 15 mg and 25 mg 17 JULY 2024 | READ MORE Glenmark receives ANDA approval for Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg (OTC) 12 JUNE 2024 | READ MORE Glenmark Pharma Reports Q4 FY2023-24 Financial results 24 MAY 2024 | READ MORE Glenmark and BeiGene Enter into an Agreement for Marketing and Distribution of Tislelizumab and Zanubrutinib in India 21 MAY 2024 | READ MORE Glenmark Pharmaceuticals receives ANDA approval for Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution, 0.2%|0.5% 17 MAY 2024 | READ MORE Glenmark Pharmaceuticals receives ANDA approval for Acetaminophen and Ibuprofen Tablets, 250 mg/125 mg (OTC) 29 APRIL 2024 | READ MORE Glenmark Pharmaceuticals Ltd. reports Consolidated Revenue of Rs. 29,096 Mn for Q3 FY 2023-24 14 FEB 2024 | READ MORE Glenmark partners with Pfizer to launch Abrocitinib in India 31 JAN 2024 | READ MORE Glenmark and Ichnos take a collaborative leap to accelerate innovation in Cancer Treatment with their alliance ‐ ‘Ichnos Glenmark Innovation’ 30 JAN 2024 | READ MORE Glenmark, Jiangsu Alphamab Biopharmaceuticals and 3D Medicines announce the signing of a License Agreement for KN035 (Envafolimab) for Multiple Geographies around the World 25 JAN 2024 | READ MORE Glenmark is the first to launch Biosimilar of Popular Anti-Diabetic Drug, Liraglutide, in India 03 JAN 2024 | READ MORE Year – 2024 Year – 2023 Year – 2022 Year – 2021 Year – 2020 Year – 2019 Year – 2018 Year – 2017 Year – 2016 Year – 2015
